11/15/2011

Sanofi division Genzyme said experimental antibody Lemtrada, or alemtuzumab, significantly cut the rate of disease relapse and risk of sustained disability worsening in patients with multiple sclerosis during a Phase III head-to-head trial with Rebif, an interferon by Pfizer and EMD Serono. Genzyme aims for an FDA submission of Lemtrada, which has fast-track status, during the first quarter.

Full Story:
Xconomy

Related Summaries